DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
66	IgA腎症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04342325 (ClinicalTrials.gov)	June 15, 2020	8/4/2020	The Clinical Trial of ADR-001 for IgA Nephropathy	Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy	Glomerulonephritis , IGA	Biological: infusion of ADR-001 (Mesenchymal stem cell)	Nagoya University	Rohto Pharmaceutical Co., Ltd.	Recruiting	20 Years	N/A	All	12	Phase 1	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04342325
(ClinicalTrials.gov)

June 15, 2020

8/4/2020

The Clinical Trial of ADR-001 for IgA Nephropathy

Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy

Glomerulonephritis , IGA

Biological: infusion of ADR-001 (Mesenchymal stem cell)

Nagoya University

Rohto Pharmaceutical Co., Ltd.

Recruiting

20 Years

N/A

All

Phase 1

Japan